Retinitis Pigmentosa

Current Location

35 Retinitis Pigmentosa Trials Near You

Power is an online platform that helps thousands of Retinitis Pigmentosa patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

AGTC-501 for Retinitis Pigmentosa

Cincinnati, Ohio
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:12 - 50
Sex:Male

75 Participants Needed

Gene Therapy for Retinitis Pigmentosa

Cincinnati, Ohio
This trial is testing a new treatment for people with a genetic eye disease that causes vision loss. The treatment uses a harmless virus to deliver a healthy gene directly into the eye. This could help improve or stabilize their vision. The study will monitor safety and effectiveness over time. This marks a significant advance in treating genetic eye diseases.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:6 - 50
Sex:Male

29 Participants Needed

BIIB111 for Choroideremia & BIIB112

Cincinnati, Ohio
The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Sex:Male

330 Participants Needed

AGTC-501 for Retinitis Pigmentosa

Cincinnati, Ohio
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:8 - 50
Sex:Male

14 Participants Needed

AGTC-501 for Retinitis Pigmentosa

Cincinnati, Ohio
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:12+
Sex:Male

24 Participants Needed

N-acetylcysteine for Retinitis Pigmentosa

Ann Arbor, Michigan
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 65

483 Participants Needed

Gene Therapy for Retinitis Pigmentosa

Ann Arbor, Michigan
This trial tests a gene therapy for people with X-linked retinitis pigmentosa. It uses a harmless virus to deliver a healthy gene to eye cells, aiming to improve their function and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating inherited retinal dystrophies, including retinitis pigmentosa.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3+

97 Participants Needed

Gene Therapy with SPVN06 for Cone-Rod Dystrophy

Pittsburgh, Pennsylvania
This trial is testing a new treatment for patients with advanced vision problems caused by specific genetic mutations. The study aims to determine the appropriate dose and evaluate its effectiveness.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

33 Participants Needed

Oral Metformin for Stargardt Disease

Ann Arbor, Michigan
Background: ABCA4 retinopathy is a genetic disease in which the ABCA4 protein is absent or faulty. It can cause waste material to collect in the eye and may cause cells to die. The cell death can lead to vision loss. Researchers want to see if an oral drug called metformin can help. Objective: To see if metformin is safe and possibly helps to slow the rate of ABCA4 retinopathy. Eligibility: People age 12 and older who have ABCA4 retinopathy and have problems with their vision. Design: Participants will be screened under a separate protocol. Participants will have a medical and family history. They will complete a questionnaire about their vision and daily activities. They will have a physical exam. They may have blood drawn through a needle in the arm. Participants will have an eye exam. Their pupils may be dilated with eye drops. Their retina may be photographed. Participants will have a visual field test. They will sit in front of a large dome and press a button when they see a light within the dome. Participants will have an electroretinogram. It examines the function of the retina. They will sit in the dark for 30 minutes. Then their eyes will be numbed with eye drops. They will wear contact lenses that can sense signals from the retinas. They will watch flashing lights. Participants will have optical coherence tomography. This non-invasive procedure makes pictures of the retina. Participants will have fundus autofluorescence. A bright blue light will be shone into their eye. Participants will take metformin by mouth for 24 months. Participants will have study visits every 6 months. Participation will last for at least 36 months....
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 100

56 Participants Needed

Gene Therapy for Retinitis Pigmentosa

Ann Arbor, Michigan
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:5+
Sex:Male

39 Participants Needed

Gene Therapy with Light-Stimulating Glasses for Retinitis Pigmentosa

Pittsburgh, Pennsylvania
This trial is testing a new gene therapy injected into the eye and special light-stimulating glasses for patients with a specific type of vision loss called non-syndromic Retinitis Pigmentosa. The gene therapy aims to fix genetic problems in the eye, while the glasses help activate the treated cells. Gene therapy has shown promise in treating retinal diseases.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

15 Participants Needed

4D-125 for Retinitis Pigmentosa

Ann Arbor, Michigan
This trial tests a new eye injection treatment for males with a genetic eye disease. The treatment replaces a faulty gene with a healthy one to help stop or slow down the disease. Gene therapy has been extensively studied and shows promise for treating genetic eye diseases by delivering functional genes to replace faulty ones.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+
Sex:Male

21 Participants Needed

VP-001 for Retinal Dystrophy

Ann Arbor, Michigan
This trial tests a new eye injection treatment called VP-001 for people with a genetic condition that affects their vision. The goal is to see if it is safe and can help the damaged cells in their eyes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

20 Participants Needed

RTx-015 for Retinitis Pigmentosa

Pittsburgh, Pennsylvania
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

18 Participants Needed

Natural History Study for Retinitis Pigmentosa

Pittsburgh, Pennsylvania
This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

82 Participants Needed

Gene Therapy for Leber Congenital Amaurosis

Ann Arbor, Michigan
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A\>G in intron 26 of the CEP290 gene ("LCA10-IVS26").
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:3+

34 Participants Needed

VP-001 for Retinal Dystrophy

Ann Arbor, Michigan
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:12+

12 Participants Needed

VP-001 for Retinal Dystrophy

Ann Arbor, Michigan
This is a repeat-dose, open-label, four arm safety and efficacy study of two doses of VP-001 administered intravitreally in participants with confirmed PRPF31 mutation-associated Retinal Dystrophy and previously treated with VP001.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

12 Participants Needed

Ultevursen for Retinitis Pigmentosa

Ann Arbor, Michigan
The purpose of this Phase 2b study is to evaluate the safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:8+

81 Participants Needed

Gene Therapy for Retinitis Pigmentosa

Erie, Pennsylvania
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:5+

150 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

OCU400 for Retinitis Pigmentosa

Chicago, Illinois
This trial tests OCU400, an eye injection, in patients with specific genetic mutations causing RP and LCA. The treatment aims to correct faulty genes to prevent vision loss.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:6+

22 Participants Needed

VR Assessment for Retinal Disease

Bethesda, Maryland
Background: The retina is a thin layer of tissue at the back of the eye. Retinal disease usually reduces a person s mobility because it affects how he or she moves through familiar and unfamiliar environments. Researchers want to see if a virtual reality (VR) tool can provide an easier and more accurate way to assess mobility. Objective: To learn if researchers can track changes in mobility in people with retinal disease using a new VR tool. Eligibility: People aged 5 and older with retinal disease that affects their vision, and healthy volunteers. Design: Participants will have 2-3 clinic visits. Participants will wear goggles or sit in front of a screen while sitting. Using a game controller, they will navigate through 4 obstacle courses presented in VR. Participants will have a medical history exam. They will answer questions about their family history. They will fill out questionnaires about the vision and mobility issues they have in their daily lives. Participants will have a complete eye exam. They will read letters from a chart. Their eye pressure will be measured. Their pupils may be dilated with eye drops. Pictures of their eye will be taken. Lights will be shined in their eyes. Participants will take a visual field test. For this, they will look into a dome and press a button when they see a light. Participants will have an electroretinogram. For this, they will sit in the dark with their eyes patched. Then their eyes will be numbed with eye drops and they will wear contact lenses while watching flashing lights. Participants will have optical coherence tomography. This is a noninvasive procedure. It produces cross-sectional pictures of the retina....
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:5+

165 Participants Needed

N-acetylcysteine for Retinitis Pigmentosa

Baltimore, Maryland
This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

30 Participants Needed

Disulfiram for Retinal Degeneration

Rochester, New York
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1

15 Participants Needed

RP1 for Skin Cancer

Victor, New York
This is a Phase 1b, single-center, open-label study, evaluating efficacy and safety of RP1 for the treatment of resectable cutaneous Squamous Cell Carcinoma in up to 12 evaluable patients. In this study, patients will receive RP1 via direct intratumoral (IT) injection into superficial cutaneous solid tumors to assess the safety and tolerability as well efficacy of RP1 treatment. The primary efficacy population is up to 12 evaluable patients with resectable CSCC. The enrollment of patients with CSCC will determine study duration.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

12 Participants Needed

Gene Therapy for Leber Congenital Amaurosis

Philadelphia, Pennsylvania
The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl). At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with RPE65 gene mutations.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3+

31 Participants Needed

Gene Therapy for Retinitis Pigmentosa

Teaneck, New Jersey
This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

20 Participants Needed

Stem Cell Therapy for Retinal and Optic Nerve Disorders

Westport, Connecticut
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

500 Participants Needed

Electro-acupuncture + TES for Retinitis Pigmentosa

Fort Lauderdale, Florida
This trial is testing a treatment called transcorneal electrical stimulation for people with retinitis pigmentosa, a condition that leads to gradual vision loss. The treatment uses small electrical currents applied to the eye to improve blood flow and stimulate retinal cells, which may help slow down vision loss. Transcorneal electrical stimulation has shown several improvements in visual function in previous studies and is currently offered by several companies.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

21 Participants Needed

OpCT-001 for Retinitis Pigmentosa

Miami, Florida
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

54 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Retinitis Pigmentosa clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Retinitis Pigmentosa clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Retinitis Pigmentosa trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Retinitis Pigmentosa is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Retinitis Pigmentosa medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Retinitis Pigmentosa clinical trials?

Most recently, we added VP-001 for Retinal Dystrophy, jCell for Retinitis Pigmentosa and Disulfiram for Retinal Degeneration to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

13 Retinitis Pigmentosa Trials near Dallas, TX

Top Retinitis Pigmentosa Clinical Trials near San Diego, CA

Top Retinitis Pigmentosa Clinical Trials near Long Beach, CA

35 Retinitis Pigmentosa Trials near Miami, FL

No Clinical Trials Found

203 Clinical Trials near Belmont, MA

186 Clinical Trials near Newton, MA

Top Transgender Clinical Trials

Top Experimental Clinical Trials

Top Leiomyosarcoma Clinical Trials

Top Ebv Clinical Trials

Top Acne Clinical Trials

By Trial

N-acetylcysteine for Retinitis Pigmentosa

Gene Therapy for Retinitis Pigmentosa

Gene Therapy for Retinitis Pigmentosa

Gene Therapy for Retinitis Pigmentosa

OpCT-001 for Retinitis Pigmentosa

Stem Cell Implantation for Retinitis Pigmentosa

Stem Cell Therapy for Retinal and Optic Nerve Disorders

Gene Therapy for Canavan Disease

APG-115 + Pembrolizumab for Skin Cancer

OpRegen for Age-Related Macular Degeneration

ARCT-810 for OTC Deficiency

Neonatal Massage for Infant Development

Related Searches

Top Smoking Clinical Trials

Top Acl Clinical Trials

Timing of Nicotine Replacement Therapy for Smoking Cessation

MR-Guided Focused Ultrasound for Breast Cancer

Nutrition Timing for Sleep Disruption in ICU Patients

Caregiver Support Intervention for Caregiver Stress Syndrome

Gene Therapy for Spastic Paraplegia

Mediterranean Diet + Tirzepatide for Crohn's Disease

Top Treatment for Intervention Clinical Trials

Metformin for Preventing Oral Cancer

Livmoniplimab + Budigalimab for Liver Cancer

Tryptophan for Celiac Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial